Aspira Pharma has several sites dedicated to the earliest discovery stage(s) supporting requests from our clients regarding novel and/or known biological targets across virtually all therapeutic areas. Our discovery teams have created real-time collaborative measures at the critical juncture of accelerating Rx discovery processes towards scale-up of New Molecular Entities (NMEs) by driving candidates towards clinical Phase I. Our services are tightly integrated with “downstream” synthetic development and manufacturing sites and can be accessed independently, or as part of a full life-cycle program involving medicinal chemistry-driven candidate analog production, lead optimization, and scale-up planning to yield drug substances.
Aspira Pharma creates highly defined early discovery teams represented by expertise in structural biology to identify and develop protein targets of interest for our clients. Our X-ray services, when combined with synthetic and computational chemistry, define the 360° coverage for definitive target confirmation:
At Aspira Pharma, the extensive experience and proven achievements of our collaborative scientists enable us to offer custom assay design through development service platform to clients ranging from pharmaceutical to biotechnology to academia/institution centers of excellence onto government R&D centers. We have the requisite bio-assays by specific molecular profile that can be applied to the following targets to rapidly drive your program towards Phase I:
For more information about our full suite of structural biology capabilities, please contact email@example.com.